Image may be NSFW.
Clik here to view.
Inovio Pharmaceuticals (NSDQ:INO) has inked an amended collaboration and licensing deal with ApolloBio for its DNA immunotherapy product designed to treat the pre-cancers caused by human papillomavirus.
The exclusive partnership is limited to China, Hong Kong, Macao and Taiwan, but it could also include the Republic of Korea over the next three years, Inovio reported. In connection with the deal, ApolloBio is slated to pay $23 million upfront and as much as $20 million later, based on certain milestones.
Get the full story at our sister site, Drug Delivery Business News.
The post Inovio lands $23m in collab with ApolloBio for HPV immunotherapy appeared first on MassDevice.
